4Q FY26 Quarterly Activity Report and Appendix 4C
Open PDF
| Stock | Adheris Health Limited (AHE.ASX) |
|---|---|
| Release Time | 23 Jul 2026, 9:20 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Adheris Health Q4 FY26 Report
Key Points
- Revenue and profit declined on pcp, reflecting the lingering impact of the challenging pharma budget cycle in the previous period.
- Achieved cashflow break-even in Q4 FY26, as previously guided.
- Net cash at period end of $9.5 million, in line with expectations.
- Strong initial momentum with customers as they enter their next pharma budget cycle.
Full Summary
Adheris Health Limited (ASX: AHE) reported a 44.6% decline in operating revenue for Q4 FY26 to $5.6 million, compared to $10.1 million in the previous year, due to lower customer renewal rates and lower bookings in the first half of FY26. Gross profit decreased, and gross margin fell by 7.1 percentage points to 35.5%. The company achieved cashflow break-even in Q4 FY26, with net operating cash inflow of $0.2 million, and net cash at period end of $9.5 million. The company is focused on advancing its key priorities, including operational scalability, digital access to pharmacy patients, and growth in non-vaccine revenue.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In